Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel.
This woman entrepreneur’s deeptech startup aims to enable digital transformation of factories using AI/ML
EmbedSense Solutions, founded by Shubha and Venkatesh Prasanna, manufactures innovative industrial-grade wireless IIOT sensors and offers value-added software solutions to manufacturing plants.
0 claps
Share on
After spending more than a decade in the corporate sector in companies like Accenture and Intel in both India and abroad,
Shubha Prasanna craved the adrenaline rush, which she felt only entrepreneurship could give her.
Her “Aha” moment came when she was first introduced to embed designs. “I realised the potential hardware development had along with software and the huge gap that existed in the Indian ecosystem, more so in the manufacturing sector. At that time, it was more of “if not now, then when?”, she says.
Covid-somnia: el fenómeno que nos provoca insomnio durante la pandemia elmanana.com.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elmanana.com.mx Daily Mail and Mail on Sunday newspapers.
Fermentation specialist NextFerm raises $9.2 million in IPO Israeli company NextFerm Technologies Inc. has raised $9.2 million in an initial public offering on the Tel Aviv stock exchange, the company announced today.
The IPO reportedly pegged the company’s value at $31.2 million. NextFerm also reportedly raised an additional $918,000 from a set of existing investors that includes Cider Holdings, Orgad Agricultural Cooperative, Ortal, Gadot, Arancia International, and Merage venture capital.
Company benefits from Enzymotec experience
NextFerm is the brainchild of former Enzymotec executives after that company was acquired by Frutarom in 2017. NextFerm’s CEO Boaz Noy headed up Enzymotec’s food ingredients division. Yossi Peled, chairman of NextFerm’s board, served in a similar position with Enzymotec.
Investigadora UPLA: la alternativa de no puranoticia.cl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from puranoticia.cl Daily Mail and Mail on Sunday newspapers.